贾纳斯激酶
STAT蛋白
鲁索利替尼
JAK-STAT信号通路
癌症研究
斯达
车站3
激酶
医学
癌症
Janus激酶1
信号转导
生物
免疫学
内科学
受体酪氨酸激酶
细胞生物学
骨髓
骨髓纤维化
作者
Dipanjan Karati,Kakasaheb R. Mahadik,Piyush Trivedi,Dileep Kumar
出处
期刊:Current Cancer Drug Targets
[Bentham Science]
日期:2022-03-01
卷期号:22 (3): 221-233
被引量:2
标识
DOI:10.2174/1568009622666220301105214
摘要
Cancer is a leading cause of death worldwide. The Janus kinase (JAK) signal transducer and activator of transcription (STAT) signalling pathway is activated abnormally, which promotes carcinogenesis. Several cytokines are important cancer drivers. These proteins bind to receptors and use the Janus kinase (JAK) and STAT pathways to communicate their responses. Cancer risks are linked to genetic differences in the JAK-STAT system. JAK inhibitors have shown to reduce STAT initiation, tissue propagation, and cell existence in preclinical investigations in solid tumour cell line models. JAK inhibitors, notably ruxolitinib, a, JAK1 or 2 blockers, make cell lines and mouse models more susceptible to radiotherapy, biological response modifier therapy, and oncolytic viral treatment. Numerous JAK antagonists have been or are now being evaluated in cancerous patients as monotherapy or by combining with other drugs in clinical studies. In preclinical investigations, certain JAK inhibitors showed promise anticancer effects; however, clinical trials explicitly evaluating their effectiveness against the JAK/STAT system in solid tumours have yet to be completed. JAK inhibition is a promising strategy to target the JAK/STAT system in solid tumours, and it deserves to be tested further in clinical studies. The function of directing Janus kinases (JAKs), an upstream accelerator of STATs, as a technique for lowering STAT activity in various malignant circumstances is summarized in this article, which will help scientists to generate more specific drug molecules in future.
科研通智能强力驱动
Strongly Powered by AbleSci AI